author-photo

Martin Gramatzki

University of Kiel
University of Erlangen-Nuremberg

340

Papers

7658

Citations

Citation Trend

Filter By

Papers (242) Sort By

Journal Conference Others

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network

2021 Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
The novel dual topoisomerase inhibitor P8-D6 shows anti-myeloma activity in vitro and in vivo

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.

2021 Biological Chemistry
Show All
- Source
- Cite
- Save
Citations (0)
Dual intracellular targeting by ruxolitinib and Mcl-1 inhibitor S63845 in IL-6 dependent myeloma cells blocks in vivo tumor growth.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy.

2020 Haematologica
Show All
- Source
- Cite
- Save
Citations (5)
Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

2020 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (2)
TANDEM AUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT: S1622

2019
Show All
- Source
- Cite
- Save
Citations (1)
Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis

2019
Show All
- Source
- Cite
- Save
Citations (1)
Targeting of CD317 by the immunotoxin HM1.24-ETA’ to allow immunotherapy in glioblastoma patients.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)